Carlsmed (CARL), a commercial-stage medical technology company that says it is “pioneering AI-enabled personalized spine surgery solutions” and is “focused on becoming the standard of care for spine fusion surgery,” priced 6.7M shares at $15.00. The deal priced within the $14.00-$16.00 range. BofA, Goldman Sachs and Piper Sandler acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.